NO941679L - Bile acid derivatives, methods of preparation and their use - Google Patents

Bile acid derivatives, methods of preparation and their use

Info

Publication number
NO941679L
NO941679L NO941679A NO941679A NO941679L NO 941679 L NO941679 L NO 941679L NO 941679 A NO941679 A NO 941679A NO 941679 A NO941679 A NO 941679A NO 941679 L NO941679 L NO 941679L
Authority
NO
Norway
Prior art keywords
preparation
acid derivatives
bile acid
methods
formula
Prior art date
Application number
NO941679A
Other languages
Norwegian (no)
Other versions
NO941679D0 (en
Inventor
Gunther Wess
Alfons Enhsen
Heiner Glombik
Werner Kramer
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO941679D0 publication Critical patent/NO941679D0/en
Publication of NO941679L publication Critical patent/NO941679L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0011—Unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det blir beskrevet gallesyrederlvater med formel I Gl - X - G2 (D hvor X har en enkelbinding eller en gruppe med formel III O O II II -[-(N)s-A-N-C-(CH2)q-C-]r-N-(B)t-, (III) Li L2 L3 Gl er en rest med formel II, R4 R8- og G2 er en rest med formel IV R9R<° (II) (IV) Det blir også beskrevet fremgangsmåte for fremstilling av disse forbindelsene. Gallesyrene med formel I har verdifulle farmakologiske egenskaper, og kan bli anvendt som legemidler.It is disclosed bile acid derivatives of formula I Gl - X - G2 (D where X has a single bond or a group of formula III OO II II - [- (N) sANC- (CH2) qC-] rN- (B) t-, (III) Li L2 L3 Gl is a residue of Formula II, R4 R8 and G2 is a residue of Formula IV R9R <° (II) (IV) Process for the preparation of these compounds is also disclosed. valuable pharmacological properties, and can be used as drugs.

NO941679A 1993-05-08 1994-05-06 Bile acid derivatives, methods of preparation and their use NO941679L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4315389 1993-05-08

Publications (2)

Publication Number Publication Date
NO941679D0 NO941679D0 (en) 1994-05-06
NO941679L true NO941679L (en) 1994-11-09

Family

ID=6487595

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941679A NO941679L (en) 1993-05-08 1994-05-06 Bile acid derivatives, methods of preparation and their use

Country Status (10)

Country Link
EP (1) EP0624593A3 (en)
JP (1) JPH07304792A (en)
AU (1) AU667009B2 (en)
CA (1) CA2123050A1 (en)
CZ (1) CZ113694A3 (en)
FI (1) FI942076A (en)
HU (1) HUT67522A (en)
IL (1) IL109579A0 (en)
NO (1) NO941679L (en)
NZ (1) NZ260470A (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289020B (en) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6107494A (en) * 1994-09-13 2000-08-22 G.D. Searle And Company Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US5583239A (en) * 1995-05-30 1996-12-10 Lehigh University Antimicrobial sterol conjugates
DE19845403B4 (en) * 1998-10-02 2005-02-10 Aventis Pharma Deutschland Gmbh Propanolamine derivatives linked to bile acids, process for their preparation, pharmaceutical compositions containing them and their use
WO2000038721A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
JP2002533414A (en) 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー Combination of ileal bile acid transport inhibitors and bile acid sequestrants for cardiovascular applications
ATE242008T1 (en) 1998-12-23 2003-06-15 Searle Llc COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND BALE ACID SEQUESTRING AGENTS FOR CARDIOVASCULAR INDICATIONS
MXPA01006472A (en) 1998-12-23 2004-03-10 Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications.
NZ512534A (en) 1998-12-23 2003-11-28 G Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
WO2000038722A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
ATE241386T1 (en) 1998-12-23 2003-06-15 Searle Llc COMBINATIONS OF ILEUMGALLIC ACID TRANSPORT INHIBITORS AND CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
WO2003040127A1 (en) 2001-11-02 2003-05-15 G.D. Searle Llc Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
BR0306643A (en) 2002-01-17 2004-10-19 Pharmacia Corp Novel hydroxy alkyl / aryl or keto tiepine compounds as inhibitors of apical bile acid sodium co-dependent transport
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
US20110294767A1 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
BR112013010705B1 (en) 2010-11-08 2020-11-17 Albireo Ab use of an ibat inhibitor and a bile acid coagulant, and pharmaceutical formulation
KR101890959B1 (en) 2010-11-08 2018-08-22 알비레오 에이비 Ibat inhibitors for the treatment of liver diseases
CN104023727B (en) 2011-10-28 2017-04-05 鲁美纳医药公司 For treating the bile acid recycling inhibitors of children's cholestatic liver disease
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
KR20230152818A (en) 2013-03-15 2023-11-03 샤이어 휴먼 지네틱 테라피즈 인크. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (en) 2013-04-26 2018-09-16 Albireo Ab Crystal modifications of elobixibat
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
CA3011565C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
RU2750937C2 (en) 2016-02-09 2021-07-06 Альбирео Аб Oral cholestyramine composition and application thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
CN110996915B (en) 2017-08-09 2023-10-03 阿尔比里奥公司 Cholestyramine pellet, oral cholestyramine preparation and application thereof
CA3100113A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
JOP20200297A1 (en) 2018-06-20 2020-11-22 Albireo Ab Crystal modifications of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
WO2020161216A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
PL3921028T3 (en) 2019-02-06 2023-02-13 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
EP3923943B1 (en) 2019-02-12 2024-07-31 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
AR120682A1 (en) 2019-12-04 2022-03-09 Albireo Ab BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
TW202134218A (en) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 Benzothiazepine compounds and their use as bile acid modulators
CN114786772B (en) 2019-12-04 2024-04-09 阿尔比里奥公司 Benzothiazepine compounds and their use as bile acid modulators
AR120679A1 (en) 2019-12-04 2022-03-09 Albireo Ab BENZOTHI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
EP4069247A1 (en) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
DK4069360T3 (en) 2019-12-04 2024-02-26 Albireo Ab BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
AR120683A1 (en) 2019-12-04 2022-03-09 Albireo Ab BENZOTHI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILIARY ACID
TW202134220A (en) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
EP4069361B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN116157389A (en) 2020-08-03 2023-05-23 阿尔比里奥公司 Benzothiazepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
EP4255565A1 (en) 2020-12-04 2023-10-11 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (en) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 Benzothia(di)azepine compounds and their use as bile acid modulators
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
US20240067617A1 (en) 2022-07-05 2024-02-29 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2024121434A1 (en) 2022-12-09 2024-06-13 Albireo Ab Asbt inhibitors in the treatment of renal diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2096614T3 (en) * 1990-12-06 1997-03-16 Hoechst Ag DERIVATIVES OF BILIAR ACIDS, PROCEDURE FOR ITS PREPARATION AND USE OF THIS COMPOUND AS A MEDICINAL PRODUCT.
AU664059B2 (en) * 1991-12-20 1995-11-02 Hoechst Aktiengesellschaft Ethylenically unsaturated bile acid derivatives, processes for their preparation and precursors
ES2111092T3 (en) * 1992-06-12 1998-03-01 Hoechst Ag DERIVATIVES OF BILIAR ACIDS, PROCEDURE FOR THE PREPARATION AND USE OF THESE COMPOUNDS AS MEDICINES.
TW289757B (en) * 1993-05-08 1996-11-01 Hoechst Ag

Also Published As

Publication number Publication date
EP0624593A3 (en) 1995-06-07
NO941679D0 (en) 1994-05-06
FI942076A (en) 1994-11-09
IL109579A0 (en) 1994-08-26
HU9401411D0 (en) 1994-08-29
CA2123050A1 (en) 1994-11-09
FI942076A0 (en) 1994-05-05
AU667009B2 (en) 1996-02-29
AU6194894A (en) 1994-11-10
HUT67522A (en) 1995-04-28
JPH07304792A (en) 1995-11-21
CZ113694A3 (en) 1994-11-16
NZ260470A (en) 1995-09-26
EP0624593A2 (en) 1994-11-17

Similar Documents

Publication Publication Date Title
NO941679L (en) Bile acid derivatives, methods of preparation and their use
NO964700L (en) Novel amino acid derivatives, processes for their preparation and pharmaceutical compositions containing these compounds
DE59408602D1 (en) Monomeric bile acid derivatives, process for their preparation and use of these compounds as medicaments
DK0610487T3 (en) Novel amino acid derivatives, processes for their preparation and pharmaceutical compositions containing these compounds
ECSP055621A (en) AZA-BICICLO-ALQUIL-ÉTERES AND ITS USE AS ALFA7-NACHR AGONISTS
NO970175L (en) Pyrido-canceled thienyl and furanyl oxazolidinones
DE59405410D1 (en) Tetrazole derivatives of gallic acids, process for their preparation and use of these compounds as medicaments
NO975987L (en) 4-Phenylaminothiazole derivatives, process for their preparation and pharmaceutical compositions containing said derivatives
NO20051047L (en) Process and intermediates for the preparation of thienopyrrole derivatives
ATE124953T1 (en) BALE ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF.
ES8406193A1 (en) Substituted 1,4-dihydropyridines, method for their preparation and their use as pharmaceuticals.
ATE4642T1 (en) 2-HYDROXYALKYL-3,4,5-TRIHYDROXYPIPERIDINES, PROCESSES FOR THEIR PRODUCTION AND USE AS MEDICINAL PRODUCTS.
DE3864636D1 (en) AMID COMPOUNDS, METHOD FOR THEIR PRODUCTION AND COMPOSITION FOR THE ACTIVATION OF GASTROMOTORIC FUNCTIONS.
ATE19875T1 (en) PYRIDINECARBONATE, PROCESS FOR THEIR PREPARATION AND USE AS A MEDICINAL PRODUCT.
DE3769563D1 (en) NEW DERIVATIVES OF 4,5-DIHYDRO-OXAZOLES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE.
NO864635D0 (en) NEW CRYSTALLINE SALTS OF ARYLOXYPHENOLAMINES AND THEIR PREPARATION.
YU3099A (en) Novel erythromycine derivatives, procedure for production and application thereof
ATE139532T1 (en) NEW DNA GYRASE INHIBITORS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
LV10504A (en) The microbiological tolerance to the sap contains the heterocyclic carboxylic acid hydroxylsane
ATE29713T1 (en) ARPHAMENIN AND ITS RELATED COMPOUNDS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS MEDICATIONS.
ATE52510T1 (en) BENZO(C&gt;-1,5-NAPHTHYRIDINE, A PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND THEIR USE AS A MEDICINAL PRODUCT.
NO984547L (en) New oxazolidine derivatives, processes for their preparation, and drugs containing these compounds
DE3851697D1 (en) 2-Amino-1,2,3,4-tetrahydroisoquinoline derivatives, process for their preparation and their use as medicines.
DE59004965D1 (en) Thienylacetic acid derivatives, processes for their preparation, their use and medicaments containing them and their production.
NO20010802L (en) New aryl or heteroarylquinolylphosphonic acid compounds, a process of their preparation and compositions containing them